Johnson & Johnson (JNJ) subsidiary Janssen Therapeutics announced that the FDA has approved an expansion to the PREZISTA (darunavir) U.S. package insert to include data from a study investigating the use of PREZISTA during pregnancy and the postpartum period. PREZISTA is indicated for the treatment of HIV-1 infection in adult and pediatric patients three years of age and older in combination with ritonavir with other antiretroviral agents. The recent label update includes dosing recommendations for pregnant women with HIV. The results show that PREZISTA taken with ritonavir was well-tolerated during pregnancy and the postpartum period.